[{"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 69, "title": "Chairman & CEO", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 7190594, "exercisedValue": 0, "unexercisedValue": 47864680}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 53, "title": "President & COO", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 4616880, "exercisedValue": 0, "unexercisedValue": 15390147}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 55, "title": "Executive VP & CFO", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 3132761, "exercisedValue": 0, "unexercisedValue": 5589906}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 60, "title": "Executive VP & COO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 3510428, "exercisedValue": 5248500, "unexercisedValue": 23376292}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 54, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 4315363, "exercisedValue": 2125307, "unexercisedValue": 9617938}, {"maxAge": 1, "name": "Dr. Thomas J. Hudson M.D.", "age": 61, "title": "Senior VP & Chief Scientific Officer of Global Research", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Perry C. Siatis", "age": 48, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay  Narayan", "title": "Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 57, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1121841, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 5, "compensationRisk": 3, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 160.81, "open": 161.16, "dayLow": 160.74, "dayHigh": 164.25, "regularMarketPreviousClose": 160.81, "regularMarketOpen": 161.16, "regularMarketDayLow": 160.74, "regularMarketDayHigh": 164.25, "dividendRate": 6.2, "dividendYield": 0.0379, "exDividendDate": 1712880000, "payoutRatio": 1.7827001, "fiveYearAvgDividendYield": 4.4, "beta": 0.564, "trailingPE": 48.747025, "forwardPE": 13.626454, "volume": 5497213, "regularMarketVolume": 5497213, "averageVolume": 5736312, "averageVolume10days": 5828180, "averageDailyVolume10Day": 5828180, "bid": 163.01, "ask": 164.0, "bidSize": 1200, "askSize": 1000, "marketCap": 290014756864, "fiftyTwoWeekLow": 130.96, "fiftyTwoWeekHigh": 182.89, "priceToSalesTrailing12Months": 5.3308597, "fiftyDayAverage": 173.3226, "twoHundredDayAverage": 157.34325, "trailingAnnualDividendRate": 6.06, "trailingAnnualDividendYield": 0.037684225, "currency": "USD", "enterpriseValue": 337130684416, "profitMargins": 0.11016, "floatShares": 1762604782, "sharesOutstanding": 1770649984, "sharesShort": 13536080, "sharesShortPriorMonth": 14691308, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0076, "heldPercentInsiders": 0.0011, "heldPercentInstitutions": 0.71781, "shortRatio": 2.11, "shortPercentOfFloat": 0.0077, "bookValue": 5.867, "priceToBook": 27.917162, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "earningsQuarterlyGrowth": 4.728, "netIncomeToCommon": 5950000128, "trailingEps": 3.36, "forwardEps": 12.02, "pegRatio": 2.35, "enterpriseToRevenue": 6.197, "enterpriseToEbitda": 12.885, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "gmtOffSetMilliseconds": -14400000, "currentPrice": 163.79, "targetHighPrice": 207.0, "targetLowPrice": 161.0, "targetMeanPrice": 183.2, "targetMedianPrice": 186.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 12816000000, "totalCashPerShare": 7.255, "ebitda": 26165499904, "totalDebt": 60579000320, "totalRevenue": 54402998272, "debtToEquity": 582.658, "revenuePerShare": 30.784, "earningsGrowth": 4.978, "revenueGrowth": 0.007, "grossMargins": 0.69027, "ebitdaMargins": 0.48096, "operatingMargins": 0.28018, "financialCurrency": "USD", "trailingPegRatio": 0.4313, "__fetch_time": "2024-05-04"}]